273 related articles for article (PubMed ID: 2730266)
1. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
2. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
3. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
4. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
5. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogs in the treatment of acromegaly.
Lamberts SW; Reubi JC; Krenning EP
Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
[TBL] [Abstract][Full Text] [Related]
7. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
8. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
9. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
10. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
Candrina R
Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
[TBL] [Abstract][Full Text] [Related]
11. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
[TBL] [Abstract][Full Text] [Related]
12. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
Kurahashi K; Endo I; Kondo T; Morimoto K; Yoshida S; Kuroda A; Aihara KI; Matsuhisa M; Nakajima K; Mizobuchi Y; Nagahiro S; Abe M; Fukumoto S
Intern Med; 2017 Sep; 56(18):2455-2461. PubMed ID: 28824054
[TBL] [Abstract][Full Text] [Related]
13. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
Gradiser M; Matovinovic M; Vrkljan M
Croat Med J; 2007 Feb; 48(1):87-91. PubMed ID: 17309144
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
15. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M
Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
[TBL] [Abstract][Full Text] [Related]
16. Medical management of acromegaly--what and when?
Melmed S
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
[TBL] [Abstract][Full Text] [Related]
17. Presurgical octreotide treatment in acromegaly.
Stevenaert A; Beckers A
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():18-20. PubMed ID: 8372606
[TBL] [Abstract][Full Text] [Related]
18. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
19. Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump.
Schatz H; Stracke H; Hildebrandt G
Pathol Res Pract; 1988 Sep; 183(5):546-51. PubMed ID: 3237541
[TBL] [Abstract][Full Text] [Related]
20. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
